J
James A. Retsema
Researcher at Pfizer
Publications - 40
Citations - 2863
James A. Retsema is an academic researcher from Pfizer. The author has contributed to research in topics: Azithromycin & Antibacterial agent. The author has an hindex of 20, co-authored 40 publications receiving 2808 citations. Previous affiliations of James A. Retsema include Yeshiva University.
Papers
More filters
Journal ArticleDOI
Ring contraction of oleandrose on the macrolide antibiotic oleandomycin with [(Methoxycarbonyl)sulfamoyl]triethylammonium hydroxide inner salt.
TL;DR: The product of this interesting rearrangement, after methanolic hydrolysis of the 2'-acetate, is the 11-acetyl-3-O-(3"-methoxy-4"-vinylfuranosyl)oleandomycin, which is only moderately less than the in vitro activity of furanoside 12.
Journal ArticleDOI
Evaluation of three 4"-deoxy-4"-sulfonamido-oleandomycin derivatives with erythromycin-like antibacterial potency.
TL;DR: Three derivatives of oleandomycin in which the C"-4 hydroxyl moiety was replaced for the first time with a nitrogen functionality have been compared and each experimental macrolide was superior to erythromycin in inhibiting RNA-directed, cell-free polypeptide synthesis.
Journal ArticleDOI
Influence of immunosuppression on the pharmacokinetics and pharmacodynamics of azithromycin in infected mouse tissues
TL;DR: Delivery and efficacy in a moderately immunosuppressed animal model are unimpaired of azithromycin, with moderate increases in Cmax and AUC values observed, relative to similar tissues from normal mice.
Journal ArticleDOI
Correlation Between the Binding of β-Lactam Antibiotics to Staphylococcus aureus and Their Physical-Chemical Properties
James A. Retsema,Verne A. Ray +1 more
TL;DR: It is proposed that, although semisynthetic cephalosporins are chemically less reactive than penicillins, they are superior to benzylpenicillin in their ability to permeate the outer surface of the Staphylococcus cell wall and irreversibly bind to reactive sites.
Journal ArticleDOI
In vitro microbiological characterization of novel cyclic homopentapeptides, CP-101,680 and CP-163,234, for animal health use.
Laura J. L. Norcia,Annette M. Silvia,John P. Dirlam,Rodney Caughren Schnur,Jay M. Bergeron,James A. Retsema,Shigeru F. Hayashi +6 more
TL;DR: Two cyclic homopentapeptides, CP-101,680 and CP-163,234, showed slightly improved in vitro potency over the viomycin analog, and both analogs showed very potent cell-free protein synthesis inhibition activity and were bactericidal against Pasteurella haemolytica, P. multocida and Actinobacillus pleuropneumoniae.